- The risk and risk factors of chikungunya virus infection and rheumatological
- 2 sequelae in a cohort of U.S. Military Health System beneficiaries: implications
- **3** for the vaccine era

1

4

6

- 5 Pollett SD^{1,2*}, Hsieh H-C^{1,2}, Lu D^{1,2}, Grance M^{1,2}, Nowak G³, Lanteri C¹, Tribble D¹, Burgess TH¹
- 7 Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics,
- 8 Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America
- 9 ²Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland,
- 10 United States of America
- ³EpiData Center, Navy and Marine Corps Public Health Center, Portsmouth, Virginia, United States of
- 12 America

13

16

- 14 * Corresponding author
- 15 Email: spollett@idcrp.org

Abstract

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Background: Understanding the risk of chikungunya virus (CHIKV) infection and rheumatic sequelae across populations, including travelers and the military, is critical. We leveraged the electronic medical records of about 9.5 million U.S. Military Health System (MHS) beneficiaries to identify the risk of post-CHIKV rheumatic sequelae. Methodology/Principal Findings: MHS beneficiary CHIKV infections diagnosed 2014-2018 were identified from the Disease Reporting System internet, TRICARE Encounter Data Non-Institutional, and Comprehensive Ambulatory/Professional Encounter Record systems. Non-CHIKV controls were matched (1:4) by age, gender, beneficiary status, and encounter date. The frequency of comorbidities and incident rheumatic diagnoses through 2020 were derived from International Classification of Diseases codes and compared between cases and controls. Logistic regression models estimated the association of CHIKV infection with rheumatic sequelae and risk factors for post-CHIKV sequelae. 195 CHIKV cases were diagnosed between July 2014 and December 2018. The mean age was 42 years, and 43.6% were active duty. 63/195 (32.3%) of CHIKV cases had an incident rheumatic diagnosis, including arthralgia, polyarthritis, polymyalgia rheumatica, and/or rheumatoid arthritis, compared to 156/780 (20.0%) of controls (p < 0.001). CHIKV infection remained associated with rheumatic sequelae (aOR = 1.911, p = 0.002) after adjusting for prior rheumatic disease and demography. Those with rheumatic CHIKV sequelae had a median 7 healthcare encounters (IQR 3-15). Among CHIKV infections, we found no association between post-CHIKV rheumatic sequelae and demography, service characteristics, or comorbidities. Conclusions/Significance: CHIKV infection is uncommon but associated with rheumatic sequelae among MHS beneficiaries, with substantial healthcare requirements in a proportion of cases with such seguelae. No demographic, clinical, or occupational variables were associated with post-CHIKV rheumatic sequelae, suggesting that prediction of these complications is challenging in MHS beneficiaries. These findings are important context for future CHIKV vaccine decision making in this and other populations.

Author summary:

We examined U.S. Military Health System (MHS) electronic medical records during to identify the likelihood of rheumatic complications after chikungunya virus (CHIKV) infection. Overall, CHIKV infections were rare in the MHS, with 195 cases found in the records between 2014 and 2018 (a period which encompassed the peak of the CHIKV epidemic in the Americas). Of these, about 32% received a rheumatic diagnosis after infection, including arthralgia, polyarthritis, polymyalgia rheumatica, and rheumatoid arthritis. Patients who had a rheumatic diagnosis had on average 7 healthcare encounters for their post-CHIKV rheumatic complication, and a quarter had more than 15 healthcare encounters. We did not find any demographic, clinical, or occupational characteristics associated with developing rheumatic complications after CHIKV, suggesting that predicting rheumatic complications from CHIKV may be challenging in MHS beneficiaries. These findings may provide important context for decisions about implementing an approved chikungunya vaccine to military servicemembers and other MHS beneficiaries.

Introduction

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus belonging to the *Togaviridae* family [1]. The ecology of CHIKV is characterized by a sylvatic cycle involving non-human primates and arboreal *Aedes* species and urban human-to-human transmission cycles involving the *A. aegypti* and *A. albopictus* vectors [1]. While CHIKV is defined by a single serotype, multiple genotypes have evolved with global geographic expansion including the Asian and descendant Asian-Caribbean lineages, and East/Central/South African and Indian Ocean lineages [1-3].

The 2013–2015 neotropical epidemic in the Americas involved over 1.6 million suspected or confirmed CHIKV cases [4]. While cases rapidly declined after the initial neotropical pandemic, there is an ongoing substantive CHIKV burden in the Americas in addition to ongoing circulation in Africa [5, 6] and Asia [7, 8]. Recently, the Pan American Health Organization issued an alert indicating the geographic range of CHIKV has expanded in the Americas, with notable resurgence in certain regions of Latin America [9-11]. Acute CHIKV infection illness is characterized by a high symptomatic-to-asymptomatic ratio, with clinical features including an abrupt onset of high fever, polyarthralgia, backache, headache, and fatigue [12]. Atypical acute CHIKV illness manifestations (e.g., acute encephalitis) are rare, potentially severe, and more often occur in the extremes of age and in those with underlying comorbidities [12-17]. Diagnosis of CHIKV infection relies on blood polymerase chain reaction (PCR) within the first week of illness and serology thereafter [18]. Management of acute CHIKV is generally supportive, with fluid replacement, analgesia and avoidance of non-steroidal anti-inflammatory drugs until dengue has been excluded as a differential diagnosis [19]. There are no current vaccines or other preventive medical countermeasures available for CHIKV aside from avoidance of vectors in endemic transmission regions [19]. Advanced vaccine development has been challenging due to the unpredictable nature of CHIKV outbreaks [20]. However, CHIKV vaccine U.S. Food and Drug Administration licensure may soon occur using a serological correlate of protection [21]. The rheumatological manifestations of CHIKV may be categorized by timing and clinical phenotype [22]. Acute CHIKV arthralgia is frequently reported and mostly occurs in mostly peripheral joints with a symmetrical pattern, although large joints can be affected [22]. Joint swelling and synovitis often accompanies this acute polyarthralgia; functional impairment during this acute phase is common due debilitating pain [22]. Chronic rheumatological manifestations typically involve the joints affected in

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

acute CHIKV arthralgia [22]. Estimates on the frequency of persistent post-acute manifestations (predominantly arthralgia or arthritis) vary significantly, with metanalysis estimates as high as 43% at 3 months, 21% at 12 months, and 14% at 18 months after initial CHIKV illness onset [22-24]. This heterogeneity is believed to reflect differences in study populations and methodologies. Pathogenesis studies have indicated that persistent host inflammation, rather than persistent synovial viral replication, plays a key role in post-CHIKV arthralgia [25, 26]. There is currently a wide variation in clinical management for chronic post-CHIKV sequelae [15] but post-acute CHIKV arthropathy is severe enough in some to warrant the use of biological or disease-modifying antirheumatic drugs [27]. While those residing in CHIKV endemic regions experience the highest burden of this arbovirus, travelers and the deploying military are also significant stakeholders for understanding the risk of CHIKV infection and post-CHIKV sequelae. There is limited published data on the burden of CHIKV in U.S. Military Health System (MHS) beneficiaries [28, 29] and none define the risk and risk factors of post-acute CHIKV sequelae in this population. Understanding the risk and risk factors of CHIKV and CHIKV sequelae is important for clinical prognostication and may support cost-effectiveness analyses for vaccine policy with potential future licensed vaccines; such findings may be generalizable to traveler populations also. The objectives in this study were to describe to characterize incident CHIKV cases that were diagnosed in the MHS between 2014–2018 and to further describe the risk and risk factors of acute and chronic post-CHIKV rheumatological sequelae in such CHIKV cases, compared to matched controls. Here, we leveraged a virtual cohort derived from over 9.5 million MHS beneficiaries, with follow-up through 2020.

Methods

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Population, setting and identification of CHIKV cases and matched controls The MHS serves approximately 9.5 million beneficiaries, including active duty servicemembers, retirees and dependents. This includes care delivered within the United States, U.S. Territories (including Puerto Rico, Guam, and the U.S. Virgin Islands), and in beneficiaries located other countries. For this study, we identified deduplicated unique CHIKV cases in MHS beneficiaries via multiple data streams from 2005 through 2018, including: (i) clinical microbiology lab (serology and PCR) results from Disease Reporting System internet (DRSi)/EpiData Center, (ii) International Classification of Diseases, 10th Revision (ICD-10) code A92.0 CHIKV disease entries from TRICARE Encounter Data Non-Institutional (TEDNI), and (iii) ICD-10 code A92.0 CHIKV disease from Comprehensive Ambulatory/Professional Encounter Record (CAPER). The treatment locations of cases were inferred by clinical provider ZIP code. To estimate the risk of post-CHIKV rheumatological sequalae, CHIKV negative MHS beneficiary controls were matched (1:4) with cases by age group, gender, date of healthcare encounter (+/- 1 month), and beneficiary status at the time of matching healthcare encounter. Controls were randomly selected within these matching strata. Demographic, post-CHIKV diagnosis and comorbidity data abstraction from the electronic medical record Demographic ICD-9 and ICD-10 code data abstracted from cases and controls (using Armed Forces Health Longitudinal Technology Application (AHLTA) and the Composite Health Care System (CHCS). The sequelae of interest were any rheumatologic disorders (See S1 Table for ICD-9 and ICD-10 codes). Comorbidity was defined as a condition/disorder (including rheumatological) which pre-existed before the

time of the first CHIKV infection diagnosis (or first matched healthcare encounter of the time-matched

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

control. We defined post-CHIKV rheumatological complications as new post-CHIKV rheumatological diagnoses with a first onset at or after the first CHIKV diagnosis (or the healthcare encounter used for matching for controls without CHIKV). When a pre-CHIKV rheumatological and post-CHIKV rheumatological diagnosis mapped to the same ICD code, we further adjudicated a pre-existing rheumatological diagnoses from a new post-CHIKV complication using DX_DESC-level diagnosis coding (Agency for Healthcare Research and Quality Clinical Classifications Software system code). A similar approach was taken for controls without CHIKV.

Statistical analysis

Demographic, clinical, and occupational characteristics of cases and controls were summarized. The frequency of rheumatological sequelae were compared in cases and controls. Conditional logistic regression (on age and sex matched cases and controls) were used to estimate the independent association between CHIKV infection and short-term (<3 months) versus long-term (≥3 months) complications, adjusting for prior comorbidities (including pre-existing rheumatological comorbidities). Unadjusted and adjusted odds ratios were presented. Finally, among those with CHIKV infections, we performed multinomial regression for any to determine risk factors for any rheumatologic related sequelae. For each multinomial regression analysis, there were 3 comparisons: participants with short-term (<3 months), long-term (≥3 months) and no sequelae.

All p values were two-sided, with an alpha significance threshold of 0.05. Analyses were conducted using SAS software (version 9.4; SAS).

Ethical considerations

This protocol was reviewed and approved for execution by the IRB of the Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.

Results

We identified 195 unique CHIKV cases diagnosed in the MHS between July 2014 and December 2018 (S1 Fig). The most frequent locations of clinical encounters were in Puerto Rico, Texas, and California, but these reflect provider ZIP codes of diagnoses (including potential diagnoses made after deployments or other beneficiary travel) and do not necessarily reflect location of where cases acquired CHIKV infections (Fig 1). Our finding of the majority of cases being diagnosed in Puerto Rico agreed with prior, smaller studies in MHS beneficiaries [29, 30]. Time series of all MHS CHIKV cases (by month) indicated the peak of MHS CHIKV cases occurring in late 2014 during the peak year of the Americas CHIKV epidemic.

Fig 1. Location of CHIKV cases by U.S. state or territory.

The median age of CHIKV cases was 42 years (IQR 31–54 years), and 43.6% were active duty servicemembers (Table 1). Compared to age, gender, beneficiary status, and healthcare encountermatched controls, cases differed from controls with respect to race (p < 0.001). Among active duty CHIKV cases, we noted that Army service and enlisted rank were most frequent; the frequency of these categories were more common than matched controls (p < 0.001; Table 1). CHIKV cases had a higher frequency of all measured comorbidities compared to age, sex, and beneficiary-matched controls (p < 0.001; Table 2).

Table 1. Demographic and professional characteristics in CHIKV cases and controls.

CHIKV negative			
controls ^a	CHIKV cases	Total	p value ^b

No. of subjects (N)	780	195	975	
Characteristic	n (n/N %)	n (n/N %)	n (n/N %)	
Gender				>.9999
Male	412 (52.82)	103 (52.82)	515 (52.82)	
Female	368 (47.18)	92 (47.18)	460 (47.18)	
Age, median, [Q1–Q3]	41 [29–56]	42 [31–54]	41 [30–55]	0.6026
Age				>.9999
≤25	84 (10.77)	21 (10.77)	105 (10.77)	
26–35	204 (26.15)	51 (26.15)	255 (26.15)	
36–45	190 (24.36)	48 (24.62)	238 (24.41)	
46–64	204 (26.15)	51 (26.15)	255 (26.15)	
65+	98 (12.56)	24 (12.31)	122 (12.51)	
Race				<.0001
White	321 (41.15)	113 (57.95)	434 (44.51)	
Black	55 (7.05)	12 (6.15)	67 (6.87)	
Asian or Pacific Islander	23 (2.95)	12 (6.15)	35 (3.59)	
Other	21 (2.69)	30 (15.38)	51 (5.23)	
Unknown	360 (46.15)	28 (14.36)	388 (39.79)	
Beneficiary				>.9999
Active duty	340 (43.59)	85 (43.59)	425 (43.59)	
Dependent	108 (13.85)	27 (13.85)	135 (13.85)	
Retiree	80 (10.26)	20 (10.26)	100 (10.26)	
Others	252 (32.31)	63 (32.31)	315 (32.31)	
Service branch ^c				<.0001
Air Force	189 (24.23)	8 (4.10)	197 (20.21)	
Army	76 (9.74)	51 (26.15)	127 (13.03)	
Coast Guard	8 (1.03)	23 (11.79)	31 (3.18)	
Other	67 (8.59)	3 (1.54)	70 (7.18)	
Not applicable	440 (56.41)	110 (56.41)	550 (56.41)	

Rank				<.0001
Enlisted	233 (29.87)	69 (35.38)	302 (30.97)	
Officer	107 (13.72)	16 (8.21)	123 (12.62)	
Not applicable	440 (56.41)	110 (56.41)	550 (56.41)	

^aControls were matched with cases by age group, gender, beneficiary and date of encounter (+/- 1 month).

Table 2. Comorbidities in CHIKV cases and controls.

	СНІК-	CHIK+	Total	p valueª
Total # of subjects	780	195	975	
Comorbidities (ICD diagnoses before time of matching)				
None	461 (59.10)	34 (17.44)	495 (50.77)	<.0001
Cancer	30 (3.85)	22 (11.28)	52 (5.33)	<.0001
Cardiovascular disease	196 (25.13)	95 (48.72)	291 (29.85)	<.0001
Chronic respiratory disease	91 (11.67)	58 (29.74)	149 (15.28)	<.0001
Mental health condition	117 (15.00)	72 (36.92)	189 (19.38)	<.0001
Osteoporosis	26 (3.33)	19 (9.74)	45 (4.62)	0.0001
Upper gastrointestinal disease	103 (13.21)	75 (38.46)	178 (18.26)	<.0001
Neurologic disease	122 (15.64)	80 (41.03)	202 (20.72)	<.0001
Rheumatologic disease	117 (15.00)	84 (43.08)	201 (20.62)	<.0001
Osteoarthritis	92 (11.79)	55 (28.21)	147 (15.08)	<.0001
Other non-traumatic joint disorders	29 (3.72)	32 (16.41)	61 (6.26)	<.0001
Rheumatoid arthritis and related disease	12 (1.54)	17 (8.72)	29 (2.97)	<.0001
Spondylosis; disc disorders; other back problems	51 (6.54)	37 (18.97)	88 (9.03)	<.0001

^ap values were calculated from a Chi-squared/Fisher's exact test.

188

182

183184

185

186

^bp-values are calculated from a Chi-squared/Fisher's exact test or Kruskal-Wallis test, as appropriate.

^cService branch and rank are only available for active duty. Other non-active duty subjects are grouped under "Not applicable" category.

We noted 63/195 (32.3%) of CHIKV cases had an incident post-CHIKV rheumatological diagnosis, compared to 156/780 (20.0%) of controls (p = 0.0002) (Table 3). Osteoarthritis, rheumatoid arthritis and related diagnoses (including inflammatory polyarthropathy), and non-traumatic joint disorder associated categories (including unspecified arthropathy, polyarthralgia and polyarthritis) were noted with statistically significant higher frequency in post-CHIKV cases versus controls (Table 3, S2 Table).

Table 3. Rheumatological sequelae in CHIKV cases and controls.

	СНІК-	CHIK+	Total	p value
No. of subjects	780	195	975	
Any rheumatic sequelae ^b	156 (20.00)	63 (32.31)	219 (22.46)	0.0002
Rheumatic sequelae by category ^c				
Infective arthritis and osteomyelitis	0 (0.00)	1 (0.51)	1 (0.10)	0.2000
Malaise and fatigue	59 (7.56)	18 (9.23)	77 (7.90)	0.4402
Osteoarthritis	2 (0.26)	4 (2.05)	6 (0.62)	0.0166
Other connective tissue disease	12 (1.54)	4 (2.05)	16 (1.64)	0.5404
Other non-traumatic joint disorders	17 (2.18)	21 (10.77)	38 (3.90)	<.0001
Other screening for suspected conditions	81 (10.38)	24 (12.31)	105 (10.77)	0.4384
Rheumatoid arthritis and related disease	2 (0.26)	7 (3.59)	9 (0.92)	0.0003

^ap values were calculated from a Chi-squared/Fisher's exact test.

Compared to controls, CHIKV infection was associated with post-infection rheumatological diagnoses (aOR = 1.91, 95% CI 1.272-2.870, p = 0.0018) after adjusting for prior the presence of any prior pre-CHIKV rheumatological diagnoses, beneficiary status, age, sex, and race (Table 4). The magnitude of this

^bSubject with more than one diagnosis code were only counted once.

^cCCS_DX_DESC category, subject may have multiple diagnosis with different categories.

effect size was larger when the outcome was stratified into short-term (≤ 3 month) post-CHIKV rheumatological diagnoses versus long-term (diagnosis recurred beyond 3 months post-CHIKV infection) rheumatic sequelae (aOR = 6.41, p < 0.001 short-term sequelae; aOR = 1.43, p = 0.09 long-term sequelae, respectively) (Table 5). Those with post-CHIKV rheumatological sequelae had a median 7 healthcare encounters for rheumatological diagnoses (IQR 3–15, range 1–33) through the period of observation.

Table 4. Unadjusted and adjusted odds ratio of CHIKV infection on rheumatic-related sequelae (n = 975).

		Una	djusted			Adj	usted ^a	
	OR	95 9	% CI	p value	OR	959	6 CI	p value
CHIK positive	1.909	1.348	2.703	0.0003	1.911	1.272	2.870	0.0018
Rheumatic related comorbidity	1.609	1.134	2.283	0.0078	1.137	0.763	1.695	0.5283
Age	1.011	1.002	1.019	0.0107	1.012	1.002	1.022	0.0181
Male	0.984	0.728	1.330	0.9171	0.918	0.620	1.358	0.6669
Race (ref: White)								
Black	1.062	0.580	1.944	0.8464	1.178	0.633	2.192	0.6055
Asian or Pacific Islander	0.846	0.359	1.995	0.7024	0.758	0.314	1.830	0.3551
Other	0.960	0.698	1.319	0.8001	1.294	0.846	1.977	0.2307
Beneficiary (ref: active duty)		,				•		
Dependents of active duty	0.591	0.353	0.990	0.0458	a —			
Retirees	0.752	0.435	1.301	0.3084	a —			
Others	1.056	0.752	1.483	0.7541	a —			
Service branch (ref: Air Force)						-		
Army	2.088	1.266	3.444	0.0039	1.582	0.930	2.691	0.0004
Coast Guard	0.564	0.187	1.702	0.3092	0.360	0.113	1.143	0.1017
Other	0.709	0.342	1.472	0.3565	0.686	0.328	1.437	0.7368

Not applicable (non-active duty)	1.039	0.697	1.550	0.8501	0.640	0.379	1.080	0.4056
Rank (ref: enlisted)						•		
Officer	1.600	0.996	2.571	0.0518	a —			
Not applicable (non-active duty)	1.016	0.721	1.431	0.9287	a —			

^aBeneficiary and rank are not included in the adjusted model due to collinearity with service branch.

Table 5. Adjusted odds ratio on rheumatic-related short-term and long-term sequelae (n = 975).

-		Short-term	(<3 month)		Long-term	(≥3 month)
	OR	959	% CI	p value	OR	95%	% CI	p value
CHIK positive	6.410	2.904	14.152	<.0001	1.428	0.947	2.153	0.0894
Rheumatic-related comorbidity	0.616	0.242	1.567	0.3087	1.329	0.878	2.012	0.1789
Age	1.018	0.997	1.040	0.0991	1.008	0.998	1.018	0.0989
Male	1.053	0.469	2.365	0.9011	1.071	0.731	1.569	0.7247
Race (ref: white)							•	
Black	1.118	0.238	5.243	0.8593	1.093	0.573	2.085	0.5557
Asian or Pacific Islander	1.614	0.336	7.748	0.6634	0.702	0.261	1.882	0.4449
Other	1.314	0.542	3.186	0.8761	1.002	0.668	1.501	0.7193

Note: 1) "No Rheumatic related sequelae" is consider as reference group for the outcome variable. 2) "Service" is excluded from the adjusted model due to quasi-complete separation of data points.

Among those with CHIKV infections, we found no association between post-CHIKV rheumatic sequelae and age, sex, race, active-duty status, or pre-existing comorbidities. Non-Army service branch and female sex was associated with a reduced odds of post-CHIKV rheumatological sequelae, but this was not statistically significant (Table 6).

Table 6. Unadjusted and adjusted odds ratio on rheumatic-related sequelae among people with CHIK infection (n = 195).

_		Unad	justed			Adjı	ısted	
	OR	95%	6 CI	p value	OR	95%	6 CI	p value
Age	1.002	0.985	1.020	0.8156	1.006	0.978	1.034	0.6969
Male (ref: female)	0.974	0.534	1.777	0.9323	0.679	0.288	1.599	0.3751
Race (ref: white)								-
Black	0.685	0.175	2.680	0.5865	0.624	0.138	2.816	0.4970
Asian or Pacific Islander	1.467	0.436	4.935	0.5356	1.350	0.376	4.853	0.4577
Other	0.924	0.468	1.826	0.8208	0.866	0.397	1.888	0.8440
Service branch (ref: Army)								_
Coast Guard	0.256	0.076	0.860	0.0276	0.275	0.077	0.979	0.0917
Other	1.461	0.395	5.407	0.5703	1.566	0.406	6.042	0.0634
Not applicable (non- active duty)	0.457	0.228	0.913	0.0266	0.341	0.141	0.828	0.0922
Comorbidities								_
Cancer	0.975	0.376	2.526	0.9586	1.029	0.324	3.269	0.9618
Cardiovascular disease	0.937	0.514	1.709	0.8320	0.799	0.371	1.720	0.5659
Chronic respiratory disease	1.431	0.751	2.725	0.2757	1.902	0.841	4.300	0.1226
Mental health condition	0.974	0.523	1.815	0.9339	0.889	0.420	1.881	0.7575
Osteoporosis	1.250	0.467	3.346	0.6569	1.488	0.390	5.680	0.5609
Upper gastrointestinal disease	0.977	0.527	1.812	0.9422	0.988	0.482	2.024	0.9737
Neurologic disease	0.757	0.408	1.403	0.3762	0.657	0.300	1.439	0.2941
Rheumatologic	1.086	0.593	1.988	0.7899	0.985	0.472	2.059	0.9688

Note: Service branch was regrouped to avoid quasi-complete separation. Other includes: Air Force and others.

Conclusion

Understanding the risk of CHIKV infection and complications in deploying U.S. military servicemembers

and other MHS beneficiaries is important, particularly with upcoming possible CHIKV vaccine licensure.

226

227

228

229

We found a very low number of CHIKV cases identified in the MHS, despite this study period covering the peak CHIKV epidemic in the Americas and leveraging data from about 9.5 million beneficiaries. Our findings correlate with low number of CHIKV infections in other U.S. MHS studies, although such studies were either smaller, earlier in the CHIKV epidemic and/or less comprehensive in their use of electronic medical record (eMR) data sources [28, 31]. Additionally, our findings correlate with a recent postdeployment serology study of 1500 deployments to South America and Puerto Rico with a low postdeployment seropositivity rate of 1.7% (highest in those serving in Puerto Rico) [32]. Our findings further agree with studies in other armed forces which also note a low frequency of CHIKV infections [28]. These low frequencies of infection may be attributed to effective personal mosquito avoidance or heterogeneity in risk exposure (for example, based on deployment role) when deployed or activated in CHIKV endemic countries or territories. Among CHIKV infections in servicemembers, we noted higher frequency Army service and enlisted ranks compared to matched servicemember controls without CHIKV; these groups have previously been noted at higher risk for other arboviruses [33, 34]. While the location of diagnosis may not reflect where the infection was acquired, the highest number of cases were diagnosed in Puerto Rico is consistent with the known high transmission of CHIKV during the neotropical epidemic [35]. While the overall number of infections was very low, we found a substantive risk of post-CHIKV rheumatological complications. We noted a considerable burden of disease with a median 7 healthcare encounters for this complication, and 25% of these complicated CHIKV cases required between 15 and 33 further encounters through the period of observation. These findings highlight that, while CHIKV infections are overall rare in MHS beneficiaries, patient morbidity in complicated CHIKV cases can be substantial, as noted in non-MHS studies [22].

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

The overall low number of CHIKV infections limited statistical power for examining risk factors for post-CHIKV sequelae. We found a non-statistically significant trend toward Army and male sex having a higher risk of rheumatic complications, but no other predictors were noted, including pre-existing comorbidities. Further study of cumulative CHIKV infections in MHS-based virtual cohorts over time may identify clearer risk factors for this complication, and this may assist in more precise prognostication of CHIKV cases in the MHS. As this study comprises the largest number of CHIKV infections in any military study, we would conclude that prediction of MHS CHIKV cases may progress to complicated rheumatological sequelae remains challenging, underscoring the need for optimal prevention of CHIKV infection. There were several strengths to this study. The use of the MHS includes a substantive number of beneficiaries who deploy or are stationed in CHIKV endemic regions and allowed for long term follow-up of cases to determine longer term complications. We derived CHIKV cases from a range of eMR data sources, including clinical microbiology laboratory results, to identify more infections than prior MHSbased studies [28-31]. Our study limitations included the use of ICD codes to diagnose CHIKV and post-CHIKV complications; prior evaluations of CHIKV ICD diagnosis coding have noted imperfect specificity [31] and this study was unable to perform chart adjudications. Conversely, CHIKV diagnoses may have been missed in some clinical presentations, and not all cases may have presented to care (including during deployments). Future directions include further studies which could also examine for non-rheumatological CHIKV sequelae such as neurocognitive complications, mood, and long-term functional impact (for example, [36, 37]). Finally, studies could leverage sera routinely collected from the U.S. military servicemembers

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

and used for arboviral research (i.e., the Department of Defense Sera Repository [32-34]) to identify prognostic and treatment related biomarkers for those beneficiaries with persistent post-CHIKV sequelae, as well as enabling ongoing serosurveillance of the risk and risk factors of CHIKV in deployed military, particularly during an era of increasing CHIKV risk in the Americas [9].

Disclaimer

The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions, or policies of Uniformed Services University of the Health Sciences; the Department of Defense; the Departments of the Army, Navy, or Air Force; the Defense Health Agency; the National Institutes of Health, the Department of Health and Human Services or the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. government. The investigators have adhered to the policies for protection of human subjects as prescribed in 45 CFR 46.

Funding statement

The protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense program executed by the Uniformed Services University of the Health Sciences through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.. This project has been funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, under an interagency agreement (Y1-AI-5072); and the Military Infectious Diseases Research Program. The authors declare no conflicts of interest.

References

302	1.	Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a
303		vaccine. Expert Rev Vaccines. 2012;11(9): 1087-1101. pmid:23151166
304	2.	Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral
305		Res. 2015;120: 32-39. pmid:25979669
306	3.	Rezza G, Weaver SC. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease
307		impact and hurdles to vaccine development. PLoS Negl Trop Dis. 2019;13(1): e0006919.
308		pmid:30653504
309	4.	54th Directing Council. Report on chikungunya virus transmission and its impact in the region of the
310		Americas. 67th Session of the Regional Committee of WHO for the Americas; September 28 to
311		October 2, 2015; Washington, DC: Pan American Health Organization and World Health
312		Organization Regional Office for the Americas. Available from:
313		https://www3.paho.org/hq/dmdocuments/2015/CD54-INF-3-e.pdf
313 314	5.	https://www3.paho.org/hq/dmdocuments/2015/CD54-INF-3-e.pdf Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of
	5.	
314	5.	Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of
314 315	5. 6.	Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-
314 315 316		Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-71. pmid:36200059
314315316317		Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-71. pmid:36200059 Asaga Mac P, Airiohuodion PE, Yako AB, Makpo JK, Kroeger A. The seroprevalence and hidden
314 315 316 317 318		Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-71. pmid:36200059 Asaga Mac P, Airiohuodion PE, Yako AB, Makpo JK, Kroeger A. The seroprevalence and hidden burden of chikungunya endemicity and malaria mono- and coinfection in Nigeria. Int J Environ Res
314 315 316 317 318 319	6.	Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-71. pmid:36200059 Asaga Mac P, Airiohuodion PE, Yako AB, Makpo JK, Kroeger A. The seroprevalence and hidden burden of chikungunya endemicity and malaria mono- and coinfection in Nigeria. Int J Environ Res Public Health. 2022;19(15): 8896. pmid:35897268
314 315 316 317 318 319 320	6.	Ushijima Y, Abe H, Mbadinga MJVM, Ondo GN, Bikangui R, Agnandji ST, et al. Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. IJID Reg. 2022;5: 68-71. pmid:36200059 Asaga Mac P, Airiohuodion PE, Yako AB, Makpo JK, Kroeger A. The seroprevalence and hidden burden of chikungunya endemicity and malaria mono- and coinfection in Nigeria. Int J Environ Res Public Health. 2022;19(15): 8896. pmid:35897268 Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The global

Pan American Health Organization, World Health Organization. Cases of chikungunya virus disease. 2023. Available from: https://www3.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikvweekly-en.html Centers for Disease Control and Prevention. Increased chikungunya virus activity in Paraguay and associated risk to travelers. 2023. Available from: https://emergency.cdc.gov/han/2023/han00487.asp 10. Pan American Health Organization, World Health Organization, Epidemiological alert: Chikungunya increase in the region of the Americas. 2023. Available from: https://www.paho.org/en/documents/epidemiological-alert-chikungunya-increase-region-americas 11. Pan American Health Organization, World Health Organization. Epidemiological alert: Increase in cases and deaths from chikungunya in the region of the Americas. 2023. Available from: https://www.paho.org/en/documents/epidemiological-alert-increase-cases-and-deathschikungunya-region-americas 12. Centers for Disease Control and Prevention. Clinical evaluation and disease. 2023. Available from: https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html 13. de Morais Alves Barbosa Oliveira R, Kalline de Almeida Barreto F, Praça Pinto G, Timbó Queiroz I, Montenegro de Carvalho Araújo F, Wanderley Lopes K, et al. Chikungunya death risk factors in Brazil, in 2017: A case-control study. PLoS One. 2022;17(4): e0260939. pmid:35389992. 14. Sharp TM, Keating MK, Shieh WJ, Bhatnagar J, Bollweg BC, Levine R, et al. Clinical characteristics, histopathology, and tissue immunolocalization of chikungunya virus antigen in fatal cases. Clin Infect Dis. 2021;73(2): e345-e354. pmid:32615591 15. Webb E, Michelen M, Rigby I, Dagens A, Dahmash D, Cheng V, et al. An evaluation of global Chikungunya clinical management guidelines: A systematic review. EClinicalMedicine. 2022;54: 101672. pmid:36193172

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

16. Pescarini JM, Rodrigues M, Paixão ES, Cardim L, Brito CAA, Costa MDCN, et al. Dengue, Zika, and chikungunya viral circulation and hospitalization rates in Brazil from 2014 to 2019: An ecological study. PLoS Negl Trop Dis. 2022;16(7): e0010602. pmid:35895718 17. Chee YS, Ahamad Fouzi N, Chong YM, Sam IC, Chan YF, Chua CL, et al. Chikungunya encephalopathy and pneumonia in a young infant presenting with septic shock. J Paediatr Child Health. 2022;58(8): 1468-1471. pmid:35175651 18. Centers for Disease Control and Prevention. Diagnostic testing. 2023. Available from: https://www.cdc.gov/chikungunya/hc/diagnostic.html 19. Centers for Disease Control and Prevention. Treatment and Prevention. 2023. Available from: https://www.cdc.gov/chikungunya/hc/treatment-prevention.html 20. Tran QM, Soda J, Siraj A, Moore S, Clapham H, Perkins TA. Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling. Vaccine. 2023;41(1): 182-192. pmid:36424258 21. Hills S. Overview of chikungunya and chikungunya vaccines. Meeting of the Advisory Committee on Immunization Practices (ACIP); October 19-20, 2022; Atlanta, Georgia: Centers for Disease Control and Prevention. 22. Suhrbier A. Rheumatic manifestations of chikungunya: Emerging concepts and interventions. Nat Rev Rheumatol. 2019;15(10): 597-611. pmid:31481759 23. Rodríguez-Morales AJ, Cardona-Ospina JA, Urbano-Garzón SF, Hurtado-Zapata JS. Prevalence of post-chikungunya infection chronic inflammatory arthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2016;68(12): 1849-1858. pmid:27015439 24. Paixão ES, Rodrigues LC, Costa MDCN, Itaparica M, Barreto F, Gerardin P, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;112(7): 301-316. pmid:30007303

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

25. Sengupta S, Bhattacharya N, Tripathi A. Increased CRP, anti-CCP antibody, IL-2R, COMP levels in prognosis of post-chikungunya chronic arthritis and protective role of their specific genotypes against arthritic manifestation. Virus Res. 2022;323: 198998. pmid:36356677 26. Dobbs JE, Tritsch SR, Encinales L, Cadena A, Suchowiecki K, Simon G, et al. Regulatory T-cells and GARP expression are decreased in exercise-associated chikungunya viral arthritis flares. Front Immunol. 2022;13: 1007106. pmid:36275717 27. Ranzolin A, Marques CDL, da Rocha Junior LF, Duarte ALBP, de Lima HD, de Almeida Martins LM, et al. Treatment with biological therapy is associated with faster recovery and lower frequency of treatment switch among rheumatic patients with chikungunya fever. Adv Rheumatol. 2022;62(1): 44. pmid:36376923 28. Frickmann H, Herchenröder O. Chikungunya virus infections in military deployments in tropical settings—a narrative minireview. Viruses. 2019;11(6): 550. pmid:31197085 29. Writer JV, Hurt L. Chikungunya infection in DoD healthcare beneficiaries following the 2013 introduction of the virus into the Western Hemisphere, 1 January 2014 to 28 February 2015. MSMR. 2015;22(10): 2-6. pmid:26505074 30. O'Donnell FL, Stahlman S, Fan M. Surveillance for vector-borne diseases among active and reserve component service members, U.S. Armed Forces, 2010-2016. MSMR. 2018;25(2): 8-15. pmid:29485891 31. Wellington T, Fraser JA, Kuo HC, Hickey PW, Lindholm DA. The burden of arboviral infections in the Military Health System 2012-2019. Am J Trop Med Hyg. 2023;108(5): 1007-1013. pmid:37037439 32. Pollett S, Lanteri C, Forshey B, Trefry S, Winkelmann E, Nasar F, et al. Serosurveillance of chikungunya infections among U.S. military personnel deploying in the Americas, 2013-2020. ASTMH 71st Annual Meeting; October 30 to November 3, 2022; Seattle, Washington: American Society of Tropical Medicine and Hygiene. Available from:

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-Meeting-Abstract-Book.pdf 33. Pollett S, Kuklis CH, Barvir DA, Jarman RG, Romaine RM, Forshey BM, et al. The seroepidemiology of dengue in a US military population based in Puerto Rico during the early phase of the Zika pandemic. PLoS Negl Trop Dis. 2022;16(1): e0009986. pmid:35061659 34. Hesse EM, Martinez LJ, Jarman RG, Lyons AG, Eckels KH, De La Barrera RA, et al. Dengue virus exposures among deployed U.S. military personnel. Am J Trop Med Hyg. 2017;96(5): 1222-1226. pmid:28193746 35. Sharp TM, Roth NM, Torres J, Ryff KR, Pérez Rodríguez NM, Mercado C, et al. Chikungunya cases identified through passive surveillance and household investigations—Puerto Rico, May 5-August 12, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(48): 1121-1128. pmid:25474032 36. Peixoto VGMNP, Azevedo JP, Luz KG, Almondes KM. Cognitive dysfunction of chikungunya virus infection in older adults. Front Psychiatry. 2022;13: 823218. pmid:35449568 37. Doran C, Elsinga J, Fokkema A, Berenschot K, Gerstenbluth I, Duits A, et al. Long-term chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curacao. PLoS Negl Trop Dis. 2022;16(3): e0010142. pmid:35231033 **Supporting information** S1 Fig. Chikungunya virus case identification from U.S. Military Health System electronic medical record systems. TEDNI-TRICARE Encounter Data Non-Institutional; CAPER-Comprehensive Ambulatory/Professional Encounter Record. S1 Table. International Classification of Diseases, 9th Revision (ICD-9) and ICD-10 codes (including cross-walked ICD-9 codes) used to identify rheumatological healthcare encounters in cases and controls.

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

- 422 S2 Table. Long description of rheumatological healthcare encounters by chikungunya virus (CHIKV)
- 423 infection status.

Fig 1.

